Brink Therapeutics is developing next-generation recombinases — ultra-precise and efficient enzymes that surpass CRISPR-Cas9. We aim to revolutionize Cell and Gene therapies, enabling large-scale production to treat cancer, genetic disorders, and other diseases.
